Your browser doesn't support javascript.
loading
The Pediatric Choroidal and Ciliary Body Melanoma Study: A Survey by the European Ophthalmic Oncology Group.
Al-Jamal, Rana'a T; Cassoux, Nathalie; Desjardins, Laurence; Damato, Bertil; Konstantinidis, Lazaros; Coupland, Sarah E; Heimann, Heinrich; Petrovic, Aleksandra; Zografos, Leonidas; Schalenbourg, Ann; Velazquez-Martin, Juan P; Krema, Hatem; Bogdali, Anna; Markiewicz, Anna; Romanowska-Dixon, Bozena; Metz, Claudia H D; Biewald, Eva; Bornfeld, Norbert; Kiratli, Hayyam; Bronkhorst, Inge H G; Jager, Martine J; Marinkovic, Marina; Fili, Maria; Seregard, Stefan; Frenkel, Shahar; Pe'er, Jacob; Salvi, Sachin M; Rennie, Ian G; Rospond-Kubiak, Iwona; Kociecki, Jaroslaw; Kiilgaard, Jens Folke; Heegaard, Steffen; Cohen, Victoria M L; Sagoo, Mandeep S; Amiryan, Anush; Saakyan, Svetlana; Eide, Nils; Krohn, Jørgen; Midena, Edoardo; Parrozzani, Raffaele; Grange, Jean-Daniel; Kilic, Emine; Blasi, Maria Antonietta; Saornil, Maria Antonia; Kivelä, Tero T.
Afiliación
  • Al-Jamal RT; Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: ranaa.aljamal@hus.fi.
  • Cassoux N; Department of Ophthalmology, Institute Curie, Paris, France.
  • Desjardins L; Department of Ophthalmology, Institute Curie, Paris, France.
  • Damato B; Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Konstantinidis L; Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Coupland SE; Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, United Kingdom; Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Heimann H; Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Petrovic A; Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles (FAA), Lausanne, Switzerland.
  • Zografos L; Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles (FAA), Lausanne, Switzerland.
  • Schalenbourg A; Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles (FAA), Lausanne, Switzerland.
  • Velazquez-Martin JP; Department of Ocular Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada.
  • Krema H; Department of Ocular Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada.
  • Bogdali A; Department of Ophthalmology and Ocular Oncology, Jagiellonian University, Collegium Medicum, Krakow, Poland.
  • Markiewicz A; Department of Ophthalmology and Ocular Oncology, Jagiellonian University, Collegium Medicum, Krakow, Poland.
  • Romanowska-Dixon B; Department of Ophthalmology and Ocular Oncology, Jagiellonian University, Collegium Medicum, Krakow, Poland.
  • Metz CH; Department of Ophthalmology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
  • Biewald E; Department of Ophthalmology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
  • Bornfeld N; Department of Ophthalmology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
  • Kiratli H; Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey.
  • Bronkhorst IH; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
  • Jager MJ; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
  • Marinkovic M; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
  • Fili M; Department of Ophthalmic Oncology, St. Erik's Eye Hospital, Stockholm, Sweden.
  • Seregard S; Department of Ophthalmic Oncology, St. Erik's Eye Hospital, Stockholm, Sweden.
  • Frenkel S; Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Pe'er J; Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Salvi SM; Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
  • Rennie IG; Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
  • Rospond-Kubiak I; Department of Ophthalmology, Poznán University of Medical Sciences, Poznán, Poland.
  • Kociecki J; Department of Ophthalmology, Poznán University of Medical Sciences, Poznán, Poland.
  • Kiilgaard JF; Department of Ophthalmology, Copenhagen University Hospital Glostrup, Copenhagen, Denmark.
  • Heegaard S; Department of Ophthalmology, Copenhagen University Hospital Glostrup, Copenhagen, Denmark.
  • Cohen VM; Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospital, London, United Kingdom.
  • Sagoo MS; Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospital, London, United Kingdom.
  • Amiryan A; Department of Ophthalmic Oncology and Radiology, Helmholtz Institute, Moscow, Russia.
  • Saakyan S; Department of Ophthalmic Oncology and Radiology, Helmholtz Institute, Moscow, Russia.
  • Eide N; Department of Ophthalmology, Oslo University Hospital-HF and University of Oslo, Oslo, Norway.
  • Krohn J; Department of Clinical Medicine, Section of Ophthalmology, University of Bergen, Bergen, Norway.
  • Midena E; Department of Ophthalmology, University of Padova, Padova, Italy.
  • Parrozzani R; G. B. Bietti Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ocular Oncology and Toxicology Research Unit, Rome, Italy.
  • Grange JD; Department of Ophthalmology, Croix-Rousse Hospital, Lyon, France.
  • Kilic E; Department of Ophthalmology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Blasi MA; Department of Ophthalmology, Catholic University of Rome, Rome, Italy.
  • Saornil MA; Department of Ophthalmology, Ocular Oncology Unit, Valladolid University Hospital, Valladolid, Spain.
  • Kivelä TT; Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ophthalmology ; 123(4): 898-907, 2016 Apr.
Article en En | MEDLINE | ID: mdl-26854035
ABSTRACT

PURPOSE:

To collect comprehensive data on choroidal and ciliary body melanoma (CCBM) in children and to validate hypotheses regarding pediatric CCBM children younger than 18 years, males, and those without ciliary body involvement (CBI) have more favorable survival prognosis than young adults 18 to 24 years of age, females, and those with CBI.

DESIGN:

Retrospective, multicenter observational study.

PARTICIPANTS:

Two hundred ninety-nine patients from 24 ocular oncology centers, of whom 114 were children (median age, 15.1 years; range, 2.7-17.9 years) and 185 were young adults.

METHODS:

Data were entered through a secure website and were reviewed centrally. Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards regression. MAIN OUTCOME

MEASURES:

Proportion of females, tumor-node-metastasis (TNM) stage, cell type, and melanoma-related mortality.

RESULTS:

Cumulative frequency of having CCBM diagnosed increased steadily by 0.8% per year of age between 5 and 10 years of age and, after a 6-year transition period, by 8.8% per year from age 17 years onward. Of children and young adults, 57% and 63% were female, respectively, which exceeded the expected 51% among young adults. Cell type, known for 35% of tumors, and TNM stage (I in 22% and 21%, II in 49% and 52%, III in 30% and 28%, respectively) were comparable for children and young adults. Melanoma-related survival was 97% and 90% at 5 years and 92% and 80% at 10 years for children compared with young adults, respectively (P = 0.013). Males tended to have a more favorable survival than females among children (100% vs. 85% at 10 years; P = 0.058). Increasing TNM stage was associated with poorer survival (stages I, II, and III 100% vs. 86% vs. 76%, respectively; P = 0.0011). By multivariate analysis, being a young adult (adjusted hazard rate [HR], 2.57), a higher TNM stage (HR, 2.88 and 8.38 for stages II and III, respectively), and female gender (HR, 2.38) independently predicted less favorable survival. Ciliary body involvement and cell type were not associated with survival.

CONCLUSIONS:

This study confirms that children with CCBM have a more favorable survival than young adults 18 to 25 years of age, adjusting for TNM stage and gender. The association between gender and survival varies between age groups.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Úvea / Neoplasias de la Coroides / Cuerpo Ciliar / Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Ophthalmology Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Úvea / Neoplasias de la Coroides / Cuerpo Ciliar / Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Ophthalmology Año: 2016 Tipo del documento: Article